The strength of tumor reactivity is uncoupled from clonal expansion among TIL-derived TCRs
摘要
Highly expanded clonotypes are widely used to enrich tumor-reactive TCRs, yet expansion may not faithfully report functional reactivity. Using direct tumor-cell recognition as the benchmark, we found that in native E0771 and LLC tumors, highly expanded clonotypes did not consistently show the strongest responses, whereas reactive TCRs were also present among low-frequency clones. We next used the antigen-controlled MB49-OVA model to jointly measure TCR functional avidity, peptide–MHC presentation abundance and tumor-cell recognition. In this setting, TCRs with different avidities for the same antigen could converge to similar expansion levels in vivo. Moreover, peptide–MHC presentation abundance was sufficient to reshape the reactivity hierarchy predicted from avidity alone, and distinct avidity–presentation combinations were linked to biased transcriptional states. Thus, clonal expansion is a context-dependent enrichment cue rather than a stable surrogate of tumor reactivity, and low-frequency clonotypes may provide a valuable reservoir for tumor-reactive TCR discovery.
参考文献
1. Tran, E., P. F. Robbins, Y.-C. Lu, T. D. Prickett, J. J. Gartner, L. Jia, A. Pasetto, Z. Zheng, S. Ray, E. M. Groh, I. R. Kriley, and S. A. Rosenberg. 2016. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N Engl J Med 375: 2255–2262.
2. Leidner, R., N. Sanjuan Silva, H. Huang, D. Sprott, C. Zheng, Y.-P. Shih, A. Leung, R. Payne, K. Sutcliffe, J. Cramer, S. A. Rosenberg, B. A. Fox, W. J. Urba, and E. Tran. 2022. Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. N Engl J Med 386: 2112–2119.
3. Caushi, J. X., J. Zhang, Z. Ji, A. Vaghasia, B. Zhang, E. H.-C. Hsiue, B. J. Mog, W. Hou, S. Justesen, R. Blosser, A. Tam, V. Anagnostou, T. R. Cottrell, H. Guo, H. Y. Chan, D. Singh, S. Thapa, A. G. Dykema, P. Burman, B. Choudhury, L. Aparicio, L. S. Cheung, M. Lanis, Z. Belcaid, M. El Asmar, P. B. Illei, R. Wang, J. Meyers, K. Schuebel, A. Gupta, A. Skaist, S. Wheelan, J. Naidoo, K. A. Marrone, M. Brock, J. Ha, E. L. Bush, B. J. Park, M. Bott, D. R. Jones, J. E. Reuss, V. E. Velculescu, J. E. Chaft, K. W. Kinzler, S. Zhou, B. Vogelstein, J. M. Taube, M. D. Hellmann, J. R. Brahmer, T. Merghoub, P. M. Forde, S. Yegnasubramanian, H. Ji, D. M. Pardoll, and K. N. Smith. 2021. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature 596: 126–132.
4. Oliveira, G., K. Stromhaug, S. Klaeger, T. Kula, D. T. Frederick, P. M. Le, J. Forman, T. Huang, S. Li, W. Zhang, Q. Xu, N. Cieri, K. R. Clauser, S. A. Shukla, D. Neuberg, S. Justesen, G. MacBeath, S. A. Carr, E. F. Fritsch, N. Hacohen, M. Sade-Feldman, K. J. Livak, G. M. Boland, P. A. Ott, D. B. Keskin, and C. J. Wu. 2021. Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. Nature 596: 119–125.
5. Lowery, F. J., S. Krishna, R. Yossef, N. B. Parikh, P. D. Chatani, N. Zacharakis, M. R. Parkhurst, N. Levin, S. Sindiri, A. Sachs, K. J. Hitscherich, Z. Yu, N. R. Vale, Y.-C. Lu, Z. Zheng, L. Jia, J. J. Gartner, V. K. Hill, A. R. Copeland, S. K. Nah, R. V. Masi, B. Gasmi, S. Kivitz, B. C. Paria, M. Florentin, S. P. Kim, K. Hanada, Y. F. Li, L. T. Ngo, S. Ray, M. L. Shindorf, S. T. Levi, R. Shepherd, C. Toy, A. Y. Parikh, T. D. Prickett, M. C. Kelly, R. Beyer, S. L. Goff, J. C. Yang, P. F. Robbins, and S. A. Rosenberg. 2022. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science 375: 877–884.
6. Pasetto, A., A. Gros, P. F. Robbins, D. C. Deniger, T. D. Prickett, R. Matus-Nicodemos, D. C. Douek, B. Howie, H. Robins, M. R. Parkhurst, J. Gartner, K. Trebska-McGowan, J. S. Crystal, and S. A. Rosenberg. 2016. Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor. Cancer Immunol Res 4: 734–743.
7. Gros, A., P. F. Robbins, X. Yao, Y. F. Li, S. Turcotte, E. Tran, J. R. Wunderlich, A. Mixon, S. Farid, M. E. Dudley, K.-I. Hanada, J. R. Almeida, S. Darko, D. C. Douek, J. C. Yang, and S. A. Rosenberg. 2014. PD-1 identifies the patient-specific CD8+tumor-reactive repertoire infiltrating human tumors. J Clin Invest 124: 2246–2259.
8. Hanada, K., C. Zhao, R. Gil-Hoyos, J. J. Gartner, C. Chow-Parmer, F. J. Lowery, S. Krishna, T. D. Prickett, S. Kivitz, M. R. Parkhurst, N. Wong, Z. Rae, M. C. Kelly, S. L. Goff, P. F. Robbins, S. A. Rosenberg, and J. C. Yang. 2022. A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers. Cancer Cell 40: 479-493.e6.
9. Simoni, Y., E. Becht, M. Fehlings, C. Y. Loh, S.-L. Koo, K. W. W. Teng, J. P. S. Yeong, R. Nahar, T. Zhang, H. Kared, K. Duan, N. Ang, M. Poidinger, Y. Y. Lee, A. Larbi, A. J. Khng, E. Tan, C. Fu, R. Mathew, M. Teo, W. T. Lim, C. K. Toh, B.-H. Ong, T. Koh, A. M. Hillmer, A. Takano, T. K. H. Lim, E. H. Tan, W. Zhai, D. S. W. Tan, I. B. Tan, and E. W. Newell. 2018. Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557: 575–579.
10. Chiffelle, J., D. Barras, R. Pétremand, A. Orcurto, S. Bobisse, M. Arnaud, A. Auger, B. N. Rodrigo, E. Ghisoni, C. Sauvage, D. Saugy, A. Michel, B. Murgues, N. Fahr, M. Imbimbo, M. Ochoa de Olza, S. Latifyan, I. Crespo, F. Benedetti, R. Genolet, L. Queiroz, J. Schmidt, K. Homicsko, S. Zimmermann, O. Michielin, M. Bassani-Sternberg, L. E. Kandalaft, U. Dafni, J. Corria-Osorio, L. Trueb, D. Dangaj Laniti, A. Harari, and G. Coukos. 2024. Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma. Immunity 57: 2466-2482.e12.
11. Morgan, D. M., B. L. Horton, V. Bhandarkar, R. Van, T. Dinter, M. Zagorulya, J. C. Love, and S. Spranger. 2024. Expansion of tumor-reactive CD8(+) T cell clonotypes occurs in the spleen in response to immune checkpoint blockade. Sci Immunol 9: eadi3487.
12. Smith-Garvin, J. E., G. A. Koretzky, and M. S. Jordan. 2009. T cell activation. Annu Rev Immunol 27: 591–619.
13. Holler, P. D., and D. M. Kranz. 2003. Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity 18: 255–264.
14. González, P. A., L. J. Carreño, D. Coombs, J. E. Mora, E. Palmieri, B. Goldstein, S. G. Nathenson, and A. M. Kalergis. 2005. T cell receptor binding kinetics required for T cell activation depend on the density of cognate ligand on the antigen-presenting cell. Proc Natl Acad Sci U S A 102: 4824–4829.
15. Kalaora, S., Y. Wolf, T. Feferman, E. Barnea, E. Greenstein, D. Reshef, I. Tirosh, A. Reuben, S. Patkar, R. Levy, J. Quinkhardt, T. Omokoko, N. Qutob, O. Golani, J. Zhang, X. Mao, X. Song, C. Bernatchez, C. Haymaker, M.-A. Forget, C. Creasy, P. Greenberg, B. W. Carter, Z. A. Cooper, S. A. Rosenberg, M. Lotem, U. Sahin, G. Shakhar, E. Ruppin, J. A. Wargo, N. Friedman, A. Admon, and Y. Samuels. 2018. Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma. Cancer Discov 8: 1366–1375.
16. Liu, Z., J. P. Li, M. Chen, M. Wu, Y. Shi, W. Li, J. R. Teijaro, and P. Wu. 2020. Detecting Tumor Antigen-Specific T Cells via Interaction-Dependent Fucosyl-Biotinylation. Cell 183: 1117-1133.e19.
17. Qiu, S., W. Li, T. Deng, A. Bi, Y. Yang, X. Jiang, and J. P. Li. 2023. Ru(bpy)32+‐Enabled Cell‐Surface Photocatalytic Proximity Labeling toward More Efficient Capture of Physically Interacting Cells. Angew Chem Int Ed e202303014.
18. Liu, H., H. Luo, Q. Xue, S. Qin, S. Qiu, S. Liu, J. Lin, J. P. Li, and P. R. Chen. 2022. Antigen-Specific T Cell Detection via Photocatalytic Proximity Cell Labeling (PhoXCELL). J. Am. Chem. Soc. 144: 5517–5526.
19. Deng, T., X. Jiang, Z. Zhao, X. Zhao, A. Bi, S. Ouyang, S. Sun, S. Qiu, M. Fan, Q. Xue, W. Yu, Y. Yang, W. Li, Y. Wu, X. Huang, D. Zhong, S. Qin, W. Zhu, and J. P. Li. 2025. CINTER-seq: Chemical profiling reveals interaction-dependent cell landscapes and gene signatures in vivo. Immunity 58: 2336-2352.e12.
20. Yadav, M., S. Jhunjhunwala, Q. T. Phung, P. Lupardus, J. Tanguay, S. Bumbaca, C. Franci, T. K. Cheung, J. Fritsche, T. Weinschenk, Z. Modrusan, I. Mellman, J. R. Lill, and L. Delamarre. 2014. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515: 572–576.
21. Kedl, R. M., W. A. Rees, D. A. Hildeman, B. Schaefer, T. Mitchell, J. Kappler, and P. Marrack. 2000. T cells compete for access to antigen-bearing antigen-presenting cells. J Exp Med 192: 1105–1113.
22. Burger, M. L., A. M. Cruz, G. E. Crossland, G. Gaglia, C. C. Ritch, S. E. Blatt, A. Bhutkar, D. Canner, T. Kienka, S. Z. Tavana, A. L. Barandiaran, A. Garmilla, J. M. Schenkel, M. Hillman, I. de Los Rios Kobara, A. Li, A. M. Jaeger, W. L. Hwang, P. M. K. Westcott, M. P. Manos, M. M. Holovatska, F. S. Hodi, A. Regev, S. Santagata, and T. Jacks. 2021. Antigen dominance hierarchies shape TCF1(+) progenitor CD8 T cell phenotypes in tumors. Cell 184: 4996-5014.e26.
指标
DOI：
Submission ID：
下载次数
已发布
如何引用
下载引用
利益冲突声明
作者声明无任何需要披露的利益冲突。
Copyright
本预印本的版权持有者为作者/资助方。
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.